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Abstract  
Aim: To test whether or not soft tissue augmentation with a collagen matrix (VCMX) 
leads to a similar increase in ridge width around dental implants compared to the use of 
an autogenous subepithelial connective tissue graft (SCTG). 
Materials and methods: In 12 dogs, immediate dental implants were placed with 
simultaneous guided bone regeneration. Three months later, soft tissue volume 
augmentation was performed by randomly allocating three treatment modalities to these 
sites (VCMX, SCTG, sham-operated group (control)). Dogs were sacrificed at 1 (n=4), 2 
(n=4) or 6 months (n=4). Descriptive histology and histomorphometric measurements 
for soft tissue thickness were performed on non-decalcified sections.  
Results: The horizontal soft tissue thickness was maximal at the most coronal level 
(alveolar crest) at 1 month (VCMX: 2.1mm±1.6mm; SCTG: 2.5mm±1.7mm; p=0.877) 
and decreased until 6 months. At 6 months, the greatest mucosal thickness was at a 
level 3.5mm below the crest (VCMX: 0.8mm±0.3mm; SCTG: 0.7mm±0.2mm) 
(p=0.754). Control sites revealed no relevant soft tissue augmentation at any level and 
any time-point. Tissue integration for VCMX and SCTG were favorable with minimal 
inflammatory reactions.  
Conclusions: Soft tissue volume augmentation at implant sites was obtained to a similar 
extent using VCMX and SCTG up to 2 months. Thereafter, degradation and remodeling 
processes were enhanced leading to a minimal increase of soft tissue thickness at 6 
months for VCMX and SCTG. 
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Clinical relevance:  
Scientific rationale for the study: Soft tissue volume augmentation around dental implant 
is usually performed using the patient’s own tissue. This therapy is associated with an 
increased morbidity due to the second surgical site. Data for soft tissue substitutes 
serving as replacements for connective tissue grafts (SCTG) are scarce. 
Principal findings: The volume stable cross-linked collagen matrix rendered an increase in 
ridge width similar to SCTG at dental implant sites. 
Practical implications: Based on previously published volumetric and histologic outcomes 
and the present data, this collagen matrix may be used as an alternative for autogenous 
soft tissue in the future.
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Introduction 
 
Soft tissue grafting procedures are routinely performed for a variety of clinical indications 
to increase the soft tissue volume in pontic sites and around dental implants, mainly for 
esthetic purposes (Studer et al., 2000, Kinsel and Capoferri, 2008, Schneider et al., 
2011, De Bruyckere et al., 2015). According to a clinical study in humans, soft tissue 
volume grafting is responsible for 43% of the final volume and therefore serves as a 
major contributor to an optimal final outcome in single-tooth implant sites (Schneider et 
al., 2011). Based on scientific evidence autogenous grafts are considered to be the gold 
standard for soft tissue volume augmentation rendering an increase ranging between 1.7 
and 3.2mm over time (Thoma et al., 2014, Thoma et al., 2009). Major disadvantages 
and limitations associated with the use of autogenous grafts, are the harvesting 
procedure and variations in quality and quantity of tissue that is available for grafting. In 
order to overcome these drawbacks and to standardize grafting procedures, soft tissue 
substitutes were introduced in the past. These devices were predominantly used to 
increase the width of keratinized tissue, for ridge preservation and recession coverage 
(Jepsen et al., 2013, Jung et al., 2013, Wei et al., 2000, Schmitt et al., 2013). In terms 
of a more extensive volume increase, these devices cannot be recommended rendering a 
limited soft tissue volume gain only (Simion et al., 2012, Jung et al., 2011). Therefore, a 
volume stable cross-linked collagen matrix (VCMX) was developed recently and evaluated 
in a number of in vitro and preclinical studies (Thoma et al., 2015, Mathes et al., 2010, 
Thoma et al., 2011a, Thoma et al., 2010, Thoma et al., 2012). The VCMX demonstrated 
favorable mechanical and biological properties, enhancing connective tissue formation 
within the collagen matrix body, undergoing simultaneous remodeling process and partial 
degradation (Thoma et al., 2015). In terms of soft tissue volume increase, the VCMX 
provided a similar gain in ridge width based on histologic and volumetric outcome 
measures when applied to chronic ridge defects (Thoma et al., 2011a, Thoma et al., 
2010). Clinically, the number of patients treated with dental implants increases and due 
to esthetic needs, soft tissue volume augmentation might be a desired therapy. 
Currently, no data are available for the use of soft tissue substitutes to increase soft 
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tissue volume at implant sites and histologic data for VCMX placed on the surface of 
implants and regenerated peri-implant bone are missing.  
The aim of the present study was, therefore, to test whether soft tissue augmentation 
with a volume stable cross-linked collagen matrix leads to an increase in ridge width at 
dental implant sites similar to those obtained by an autogenous subepithelial connective 
tissue graft. 
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Material and Methods 
 
Study Design 
The present study was designed as a randomized controlled experimental study and 
conducted in accordance with the OECD Good Laboratory Practice regulations, 
ENV/MC/CHEM (98) 17, with the European Good Laboratory Practice regulations, 
2004/10/EC Directive and with the United States Food and Drug Administration Good 
Laboratory Practice regulations, 21 CFR 58. The protocol was approved by the local 
ethical committee of NAMSA (Lyon, France) on September 9, 2013. Twelve adult male 
beagle dogs (about 2 years old), weighing 11 ± 3 kg, were kept in a purpose-designed 
room for experimental animals and fed a soft diet during the entire study period.  
Animal preparation and medication 
The dogs were fasted for food 12 to 24 hours before the surgeries. Spiramycin and 
metronidazole (Buccoval®, Sogeval) were administered per os and penicilline, procaine 
and benzathine (Duplocilline®, Intervet S.A) were injected subcutaneously the day 
before surgery. After an intramuscular injection of medetomidine (Dorbene Vet®, Pfizer), 
anesthesia was performed by intravenous administration of ketamine (Ketamine 1000®, 
Virbac) and atropine (Atropinum Sulfuricum, Aguettant) followed by inhalation of an O2 – 
isoflurane mixture (Isoflo®, Axience). A pre-operative subcutaneous injection of 
carprofene (Rimadyl®, Pfizer) and buprenorphine (Buprecare®, Axience SAS) was 
additionally administered. An intravenous infusion with an electrolyte solution was 
performed during surgery (Ringer lactate, CEVA Santé Animal). The dogs were placed on 
a heating pad and the mandibles disinfected by application of a 0.2% chlorexhidine 
solution (Cooper). Prior to the beginning of the surgeries, injections of 2% lidocaïne with 
adrenaline (Lidocaïne adrenaline®, Aguettant) were administered for each hemi-
mandible. An overview on the schedule of the study is displayed in Fig. 1. 
Extractions and implant placement 
Following elevation of a muco-periosteal flap on the lingual and buccal side 
between M2 and P1, all mandibular mesial roots of P3, P4, and M1 were extracted and 
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the buccal bone plates removed (Fig. 2A). The distal roots of each P3, P4, and M1 were 
root canal treated according to a previously described procedure (Thoma et al., 2010). A 
two-piece dental implant (Straumann BoneLevel, 3.3mmx8mm, Institut Straumann AG, 
Basel, Switzerland) was placed in the area of the mesial root of P3, P4 and M1 with the 
implant shoulder at the level of the lingual bone crest (Fig. 2B). The buccal peri-implant 
dehiscence and infrabony defects were regenerated with demineralized bovine bone 
mineral (Bio-Oss®, (0.25-1mm) Geistlich Pharma AG, Wolhusen, Switzerland) (Fig. 2C). 
A native collagen membrane (Bio-Gide®, Geistlich Pharma AG, Wolhusen, Switzerland) 
was applied to cover the augmented area (Fig. 2D). Following rinsing with sterile saline 
and releasing incisions within the periosteum, primary wound closure was obtained with 
non-resorbable sutures (GoreTex 5-0®, GoreTex, Germany) (Fig. 2E). 
Soft tissue augmentation 
Soft tissue augmentation surgeries were performed on one side of the mandible at 25 
weeks and repeated on the contralateral side at 29, 42 or 45 weeks (both post implant 
placement) (Fig 3a). For that purpose, sulcular incisions were made around P1 and P2, 
the remaining roots of P3, P4 and M1 and partial-thickness flaps elevated, thereby 
preparing a pouch on the buccal side of the implants. Subsequently, three treatment 
modalities were randomly applied to the defect sites according to a computer-generated 
randomization list:  
• Volume stable cross-linked collagen matrix made of porcine collagen (VCMX) 
(Fibro-Gide, Geistlich Pharma AG, Wolhusen, Switzerland) 
• autogenous subepithelial connective tissue graft (SCTG) 
• sham-operated site (control)  
The VCMX is designed as a matrix for submerged healing and to serve as a replacement 
for the autogenous subepithelial connective tissue graft (Thoma et al., 2016). The matrix 
is characterized by a loose network, is cross-linked and made of porcine collagen. It 
combines the stability of cross-linked collagen membranes (Brunel et al., 1996) and the 
favorable tissue integration of non-cross-linked collagen membranes (Thoma et al., 
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2011b), but does not have a membrane function. The VCMX (dimension: 10 mm x 
7.5mm x 5mm) was positioned in the pouch underneath the elevated buccal flap. The 
VCMX was stabilized with a horizontal mattress suture connecting it to the lingual flap 
(Dafilon® 5-0, B. Braun Melsungen AG, Melsungen, Germany)(Fig. 3b1). The SCTG was 
harvested from the lateral part of the palatal vault (Thoma et al., 2010). Fatty, and 
glandular tissue, as well as remnants of the epithelium were removed, resulting in a 
dimension (thickness) similar to the VCMX. Compression with a sterile gauze and 3 to 4 
single sutures (Dafilon® 5-0, B. Braun Melsungen AG, Melsungen, Germany) were used 
to reposition the epithelial coverage at the palatal donor site. The SCTG was then 
positioned in the buccal pouch under the elevated flap and immobilized using a horizontal 
mattress suture connecting it to the lingual flap (Dafilon® 5-0, B. Braun Melsungen AG, 
Melsungen, Germany) (Fig 3b2). In control sites no further augmentation was performed 
(Fig 3b3). Subsequently, in all sites, periosteal releasing incisions were made to allow for 
a tension-free primary wound closure using one horizontal mattress suture and four to 
five single sutures (Dafilon® 5-0, B. Braun Melsungen AG, Melsungen, Germany) (Fig. 
3c). Suture removal was performed 14 days later and the sites were macroscopically 
inspected. 
 
Sacrifice 
At 1, 2 and 6 months post soft tissue augmentation, euthanasia was performed by a 
lethal injection of a barbiturate (Dolethal®, Vetoquinol). The hemi-mandibles were 
sampled en bloc and fixed in 4% neutral buffered formalin for histopathologic analysis.  
 
Histologic preparation 
After initial fixation, the hemi-mandibles were dissected into individual blocks with a 
band saw (one block per site) and fixed again in 4% neutral buffered formalin. After 
complete fixation, the sites were dehydrated in alcohol solutions of increasing 
concentration, cleared in xylene and embedded in polymethylmetacrylate (PMMA). One 
central bucco-lingual cross section through the dental implant was performed by a 
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microcutting and grinding technique (approximately 40 to 50µm thick) (Donath and 
Breuner, 1982). The histologic slides were stained with a modified polychromatic stain 
(Paragon) for qualitative, semi-quantitative and quantitative histopathologic analysis. 
Descriptive histology 
The histologic sections were analyzed by light microscopy (Nikon Eclipse 80i, objectives: 
x2, x10, x20, x40 and x60) equipped with a color image analyzing system Tribvn® 
(Tribvn, Chatillon). A qualitative and semi-quantitative evaluation of the tissue effects 
was performed in adaptation to ISO 10993 6 and in compliance with the standard 
nomenclature of the International Society for Stereology (Exner, 1987). 
Histomorphometric measurements 
The histomorphometric outcomes were assessed according to Fig. 4. For that purpose, 
the borders of the prepared pouch underneath the buccal flap augmented with the VCMX, 
the SCTG or left empty (control) were defined. A horizontal line (bucco-lingual axis) was 
drawn at the top of the lingual crest, perpendicularly to the dental implant (green line in 
Fig. 4). A vertical line (corono-apical axis) was then drawn perpendicularly to this 
horizontal line, at the level of the top of the threads of the implant (orange line in Fig. 4). 
Four additional lines (blue) were drawn perpendicularly to the vertical line at four 
different levels (1.5mm, 3.5mm, 5.5mm and 7.5mm) below the horizontal line. The ridge 
width (bucco-lingual axis) was measured along these horizontal lines (green and blue 
lines) for implant, bone marrow, bone substitute material, bone, pouch with the VCMX, 
SCTG or empty control (=augmented soft tissue thickness) and native soft tissue (Fig. 
4).  
Statistical analysis 
Data was summarized in terms of means and standard deviations. The local tissue 
effects and performance were compared among groups and time-points as follows: VCMX 
versus SCTG and control; SCTG versus control; for each group, comparison between the 
different time periods (1, 2 and 6 months). The local tissue effects were evaluated based 
on comparison of the semi-quantitative histopathologic inflammatory parameters. No 
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statistical analysis was performed for these parameters. The performance evaluation was 
based on the semi-quantitative histopathologic evaluation and the quantitative 
histomorphometric evaluation. For that purpose, a statistical analysis was conducted (5% 
risk) with a statistical software (Software SPSS version 19.0, SPSS inc.) for the 
augmented soft tissue thickness. 
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Results 
Clinical and macroscopic findings 
The dogs remained healthy and neither systemic complications nor local intolerances at 
the augmented sites occurred during the entire study period. Some soft tissue 
dehiscences or delayed wound healing, however, occurred after extractions and implant 
placement (one side in two dogs) as well as after soft tissue augmentation surgeries (one 
side in two dogs). These observations were not correlated to any treatment group and all 
sites healed without further treatment. 
Descriptive histology 
In general, inconsistent signs of osseointegration of the bone graft particles were 
observed. Frequent signs of fibrous encapsulation and/or loss of the bone graft particles 
were noted. A moderate to marked grade horizontal and/or vertical bone regeneration 
was observed up to 6 months irrespective of the groups. This often led to buccal implant 
surfaces being covered by soft tissues. In some sites the native collagen membrane 
persisted over time and was still visible up to 6 months.  
VCMX: At 1 month, a slight to moderate infiltration of macrophages and 
lymphocytes and a limited number of plasma cells was observed (Fig 5a). The VCMX was 
integrated and slightly to moderately degraded (Fig. 5b). A slight to moderate grade of 
soft tissue augmentation and vertical bone growth was observed. At 2 months, the VCMX 
network was integrated, moderately degraded and slightly infiltrated by macrophages, 
lymphocytes and plasma cells. A slight soft tissue augmentation and a moderate grade of 
vertical bone growth were observed. At 6 months, no signs of local inflammation were 
visible anymore. A null to slight soft tissue augmentation and a moderate to marked 
grade of vertical bone growth were evident. In addition, discrete signs of mineralization 
were noted in one out of eight sites. The VCMX was completely integrated and markedly 
to severely degraded (Fig 5c). 
SCTG: At 1 month, no significant local inflammation was observed (Fig. 5d). The 
SCTG was integrated, remodeled and degraded to a moderate to marked degree. A slight 
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soft tissue augmentation and a marked grade of vertical bone growth occurred. One site 
demonstrated discrete signs of mineralization. From 2 months on, no local inflammation 
or mineralization was observed (Fig 5e). The SCTG was not clearly identifiable and was 
considered fully degraded at 2 months. No obvious signs of soft tissue augmentation 
were evident, whereas a marked grade of bone growth had occurred. At 6 months, no 
soft tissue augmentation, but a moderate to marked grade of bone growth was evident 
(Fig 5f).  
Control: The tissues were healed at 1 month. Soft tissue augmentation, local 
inflammation and signs of mineralization were not observed at any time-point. Bone 
formation, however, increased over time up to a marked grade at 6 months (Fig 5g). 
Histomorphometric outcomes (horizontal soft tissue thickness) 
All data are displayed in Table 1 and Appendix 1. Other than reported, no statistically 
significant differences were observed between the groups for any of the outcomes 
measures (Table 2; p>0.05).  
In general, the augmented soft tissue thickness for VCMX and SCTG were highest at the 
level 0mm at 1 month and decreased to the level 7.5mm up to 6 months. Control sites 
revealed no relevant augmented soft tissue thickness at any level and any time-point 
(range: 0.07mm to 0.66mm).  
At 1 month, VCMX and SCTG showed overall higher values of augmented soft tissue 
thickness at all apico-coronal ridge height levels compared to the control group. At 
1.5mm and 3.5mm, the VCMX group had significantly more soft tissue gain compared to 
the control group (p= 0.011; p= 0.019), whereas the SCTG group had significantly more 
soft tissue gain at 0mm and 1.5mm compared to the control group (p= 0.019; p= 
0.012) (Table 2). 
At 2 months, the VCMX and SCTG groups showed overall higher values of augmented 
soft tissue thickness at all apico-coronal ridge height levels compared to the control 
group, even though VCMX and SCTG values decreased when compared to 1 month. The 
differences between VCMX and control were significant at 3.5mm (p=0.030) (Table 2).  
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At 6 months, VCMX and SCTG demonstrated a higher gain of augmented soft tissue 
thickness at all apico-coronal ridge height levels compared to the control group. Again, 
the overall number of VCMX and SCTG had decreased from 2 months. At 3.5mm, the 
VCMX group yielded significantly higher values of augmented soft tissue thickness 
compared to the control group (p= 0.015). At 5.5mm, the SCTG group yielded 
significantly higher values compared to control group (p= 0.025) (Table 2.) 
Other than reported, none of the differences for augmented soft tissue thickness were 
statistically significantly different between the groups (p>0.05) (Table 2). 
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Discussion 
The present experimental study revealed that i) soft tissue volume increase could be 
obtained using VCMX and SCTG, ii) control sites did not show any gain in soft tissue 
thickness, iii) augmented soft tissues underwent major remodeling processes over time 
and, iv) these remodeling and degradation processes lead to a decrease in the 
augmented soft tissue thickness between 2 and 6 months for VCMX and SCTG. 
The stability and thickness of augmented soft tissues is considered to be a contributing 
factor for the success of dental implants and helps to facilitate the choice of the 
reconstructions (Brito et al., 2014, Jung et al., 2008). This is based on clinical data that 
demonstrate soft tissue surgeries contribute to more than 40% of the final 
horizontal/buccal volume with minimal changes up to one year (Schneider et al., 2011), 
as well as the critical threshold value of the mucosal thickness being 2mm (Jung et al., 
2007). In case less than 2mm of buccal mucosal thickness is present, the use of a metal 
abutment may lead to a greyish discoloration of the mucosa, whereas all-ceramic 
reconstructions are more favorable in terms of esthetics (Jung et al., 2008, van Brakel et 
al., 2011). This in turn means that a certain mucosal thickness may be desired to leave 
more freedom in the choice of the reconstruction material. Autogenous SCTGs are still 
considered to be the gold standard and data on soft tissue substitutes for soft tissue 
volume augmentation are limited to preclinical data or limited to devices not primarily 
intended to be used for volume increase (Thoma et al., 2014). The outcomes of the 
present study revealed a similar and successful increase in mucosal thickness at implant 
sites at 1 and 2 months. This is in line with previous data comparing the same two 
treatment modalities (VCMX and SCTG) for soft tissue volume augmentation in chronic 
ridge defects (Thoma et al., 2011a). In that study, a volume increase at 1 month and 
stability of the augmented region up to 3 months was documented. That study also 
revealed that both soft tissue grafts underwent remodeling and degradation processes. 
For the VCMX, more bone formation and a slightly higher loss of ridge width (in terms of 
soft tissue) was observed. A different study design was chosen for the present 
experimental trial. Immediate implant placement with simultaneous GBR was performed. 
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Even though a healing time of 25 and 45 weeks was initiated prior to soft tissue 
augmentation - and in contrast to previous data with chronic ridge defects - a more 
acute situation was present. These sites probably underwent changes in terms of 
maturation and regeneration of the hard tissue augmentation, which might have 
contributed to a more reactive environment for the soft tissue grafts on top. In addition, 
as identified on the histologic slides, the GBR procedure was not as successful as 
expected. A major part of the applied biomaterials was lost (probably due to 
encapsulation within the soft tissues) or displaced more apically. This resulted in implant 
surfaces being exposed to the soft tissues. As clearly visible on the histologic slides, 
VCMX and SCTG were placed in part on these exposed implant surfaces without 
underlying bony support (Fig. 5). These two reasons could explain, why both soft tissue 
grafts, VCMX and SCTG, underwent more extensive remodeling and degradation 
processes and demonstrated only a limited increase in augmented soft tissue thickness 
at 6 months. Moreover, in the previously published study (Thoma et al., 2010), the 
augmented soft tissues (both VCMX and SCTG) had a higher initial thickness (augmented 
thickness: 10mm, uncompressed). This is in contrast to the present study, where SCTG 
and VCMX were not folded and had a thickness of roughly 50% (5mm) compared to the 
previous experimental trial. Still, remnants of the transplanted SCTG and of the matrix 
body (VCMX) could be identified at the last sacrifice time-point (6 months). This is, for 
VCMX, in line with a previous study in rats (Thoma et al., 2015). In that study, VCMX 
was placed in subcutaneous pouches and followed up to 6 months. Similar to the present 
study, remnants of the matrix could be observed, but the thickness of the VCMX had 
been decreased. Another explanation for the minimal soft tissue thickness, slightly higher 
than control sites, could be that the ridge was augmented outside the bony envelope. It 
has been speculated that in cases where bone regeneration is attempted by 
overcontouring the ridge (bone regeneration outside the bony envelope), the obtained 
final ridge width is suboptimal with an increased rate of buccal bone loss or an only 
limited gain (Garaicoa et al., 2015, Park et al., 2009). In terms of soft tissues, one might 
speculate that the minimal increase, observed at 6 months, might be due to the 
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augmentation outside of the bony envelope . SCTGs had been used in the past to 
augment chronic ridge defects and controlled up to 5 years post insertion of the final 
fixed dental prosthesis (Sanz Martin et al., 2016). The study revealed stable soft tissues 
and a minimal decrease in height and volume over 5 years. Control sites without soft 
tissue grafting demonstrated the same stability as SCTG sites. This long-term stability 
might reflect that once augmented soft tissues are stimulated by the pontic of a fixed 
dental prosthesis, these sites might undergo less volumetric changes. 
The descriptive histology and semi-quantitative analyses demonstrated that the 
augmented SCTG integrated and subsequently remodeled and degraded to a marked 
grade without a significant inflammation at 1 month. At the same time, bone formation 
had taken place underneath the SCTG. Data of a previous study with a similar set-up 
(Thoma et al., 2011a), but chronic ridge defects that were augmented, revealed a similar 
limited inflammatory reaction. The borders to the underlying bone, however, were 
distinct. This might be explained by the chronic defects, whereas in the present study, 
remodeling and maturation processes from the underlying GBR materials were ongoing 
and resulted in a less distinct border towards the bone. From 2 months on in the present 
study, the SCTG was not clearly identifiable and degraded to a marked grade leaving 
almost no augmented soft tissue left at 6 months. The native soft tissue, however, 
increased during the entire study period in all groups. This observation could have in part 
compensated the loss of the augmented area and might be explained by difficulties to 
assed the border between augmented and native soft tissue. The observation that soft 
tissues demonstrate spontaneous thickening and can compensate for missing hard tissue 
on the buccal side of dental implants has been reported in clinical studies (Benic et al., 
2012, Kuchler et al., 2016, Chappuis et al., 2015). In terms of collagen-based soft tissue 
substitutes and membranes, a variety of preclinical and clinical studies have been 
published in the past. Based on these experiments, degradation, tissue integration and 
angiogenesis were predominantly influenced by the composition of the 
membranes/matrices with more favorable biological attributes for native non-cross-
linked collagen-based materials compared to controls (Rothamel et al., 2012, Schwarz et 
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al., 2006, Rothamel et al., 2004). For VCMX, previous data revealed ongoing long-term 
remodeling processes up to 6 months in a mouse model (Thoma et al., 2015) and up to 
3 months in a canine model (Thoma et al., 2011a). At 1 month, in both studies, the 
VCMX was fully integrated without clear distinction to the surrounding tissues and 
thereby demonstrated favorable biologic properties enhancing connective tissue 
formation. Similar to previous data, a marked degradation was observed up to the 6-
month time-point. The VCMX were partially replaced by newly formed connective tissue, 
but left only a minimal soft tissue thickness. In contrast to SCTG sites, VCMX sites 
demonstrated a slight to moderate infiltration of inflammatory cells at 1 and 2 months, 
but not at 6 months. Tissue integration of (non)cross-linked collagen membranes and 
matrices has been investigated previously. In an ectopic mouse model, two prototype 
VCMX were implanted in subcutaneous pouches. The inflammatory reaction at 3 and 6 
weeks was limited (Thoma et al., 2012). In contrast, similar to the present study, a 
significantly elevated number of inflammatory reactions in the adjacent soft tissues was 
observed in a clinical study using a cross-linked membrane (Becker et al., 2009). 
Whereas in the latter clinical study, this adverse tissue reaction resulted in an early 
exposition of GBR membranes, the VCMX in the present study did not demonstrate any 
such outcomes and further healing was uneventful without an elevated number of 
inflammatory cells at 6 months. In a recent clinical study, biopsies of VCMX were 
obtained 3 months post soft tissue augmentation. Histologic analyses demonstrated the 
presence of a limited number of inflammatory cells, but no adverse tissue reactions or an 
increased rate of dehiscences compared to sites treated with SCTGs (Thoma et al., 
2016).  
In the present study, histologic slides were analyzed for mineralization within the 
augmented soft tissues, thereby assessing the biocompatibility and local tolerance of the 
soft tissue substitute (VCMX) and the transplanted autogenous grafts (SCTG). For both 
VCMX and SCTG, mineralization was observed in one site only at one time-point only. 
This underlined that the grafting materials could be safely used without hampering tissue 
integration and elicited biocompatibility.  
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From a clinical point of view, the present study indicated that both VCMX and SCTG, 
could be used for soft tissue augmentation at implant sites. Clinicians need to be aware 
of ongoing hard and soft tissue remodeling processes that could change the tissue 
architecture. It remains unknown, however, how the augmented soft tissues would 
behave if pressure or stimulation is applied by reconstructions once dental implants are 
loaded or FDPs inserted in these areas. Future research is needed to determine an 
optimal time-point to start conditioning of augmented soft tissues (with VCMX and SCTG) 
at implant sites.  
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Conclusion 
The cross-linked volume-stable collagen matrix and the subepithelial connective tissue 
graft rendered a similar gain in ridge width at sites where implants with simultaneous 
guided bone regeneration had been placed. The ridge width was predominantly increased 
at 1 and 2 months for VCMX and SCTG sites. The augmented areas underwent 
continuous and enhanced remodeling processes, both, on the hard and soft tissue level. 
At 6 months, most of the VCMX network and the augmented SCTG had been degraded 
and/or replaced leaving only a minimal increase in soft tissue thickness. VCMX sites 
demonstrated a slight to moderate infiltration with inflammatory cells during the first 2 
months, whereas in SCTG sites, no inflammation was present. Adverse tissue reactions 
such as local intolerance or issues with biocompatibility were negligible for VCMX and 
SCTG. Both VCMX and SCTG can be used for soft tissue augmentation at dental implant 
sites, however, rendering short-term gain in ridge width only. 
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Figure legends 
 
Figure 1. 
Overview of the study schedule. 
Figure 2. 
Clinical situation at the time of extraction and immediate implant placement. 
A Occlusal view of a lower right mandible with extracted mesial roots of teeth P3, P4, M1.  
B Immediate implant placement in the extraction sites.  
C Guided bone regeneration performed on the buccal aspect of the implants using 
deproteinized bovine bone material (DBBM). 
D Implant sites and DBBM material covered with resorbable collagen membranes. 
E Wound closure using non-resorbable sutures.  
 
Figure 3. 
Clinical situation at the time of soft tissue augmentation.  
a Occlusal view before the surgical intervention.  
b Augmentation sites according to randomization for the respective groups: 
1. volume-stable collagen matrix (VCMX) at the central site 
2. autogenous subepithelial connective tissue graft (SCTG) at the mesial site 
3. sham-operated site (control) at the center of the picture 
c Occlusal view after suturing.  
 
Figure 4.  
Template used for the histomorphometric measurements depicting the different 
evaluated areas (bone, bone substitute, non-mineralized tissue, augmented area, 
covering flap) and the five levels used for the horizontal measurements. 
 
Figure 5.  
Histologic slides stained with Paragon of the three groups at the different time points.  
a Group VCMX at 4weeks (0.5x magnification). 
b high resolution image of VCMX at the center of the augmented area at 4weeks (100x 
magnification) 
c Group VCMX at 24weeks 
d high resolution image of SCTG at the center of the augmented area at 4weeks (100x 
magnification) 
e Group SCTG  at 8weeks (0.5x magnification).  
f Group SCTG at 24weeks (0.5x magnification).  
28 
 
 
G Group Control (sham-operated site) at 8weeks (0.5x magnification).  
AC=adipocytes; BV=blood vessel; CF=covering flap; CT=connective tissue; 
SCTG=autogenous subepithelial connective tissue graft; VCMX=volume-stable collagen 
matrix 
 
 
Table 1.  
Summary of the histomorphometric measurements in horizontal thickness of the 
augmented soft tissue thickness at the different time points (4, 8, and 24 weeks).  
Measures are depicted for the three groups SCTG (subepithelial connective tissue graft); 
VCMX (volume stable cross-linked collagen matrix) and sham-operated site (control) at 
five different levels perpendicular to the implant axes (0mm, 1.5mm, 3.5mm, 5.5mm, 
7.5mm) 
Mean, standard deviations (SD), and Medians were calculated with a confidence interval 
(CI) of 95%. 
  
Table 2.  
Inter-group comparison of the augmented areas for the groups SCTG (subepithelial 
connective tissue graft), control (sham-operation) and VCMX (volume stable cross-linked 
collagen matrix) were calculated at 4, 8, and 24 weeks at the five different levels. 
*Significant p-values.   
 
Appendix 1. 
 
Summary of the histomorphometric measurements in horizontal thickness of the different 
areas (implant, bone marrow, bone substitute material, bone, native soft tissue) at the 
different time points (4, 8, and 24 weeks).  
Measures are depicted for the three groups SCTG (subepithelial connective tissue graft); 
VCMX (volume stable cross-linked collagen matrix) and sham-operated site (control) at 
five different levels perpendicular to the implant axes (0mm, 1.5mm, 3.5mm, 5.5mm, 
7.5mm) 
Mean, standard deviations (SD), and Medians are calculated with a confidence interval 
(CI) of 95%. 
 
 
 
Table 1 
 
  4 weeks 8 weeks 24 weeks 
  SCTG VCMX Control SCTG VCMX Control SCTG VCMX Control 
  Mean 
SD 
Median 
95% CI  
(low and up) 
Mean 
SD 
Median 
95% CI 
(low and up) 
Mean 
SD 
Median 
95% CI 
(low and up) 
Mean 
SD 
Median 
95% CI 
(low and up) 
Mean 
SD 
Median 
95% CI 
(low and up) 
Mean 
SD 
Median 
95% CI 
(low and up) 
Mean 
SD 
Median 
95% CI 
(low and up) 
Mean 
SD 
Median 
95% CI 
(low and up) 
Mean 
SD 
Median 
95% CI 
(low and up) 
A
ug
m
en
te
d 
so
ft 
tis
su
e 
th
ic
kn
es
s 
(h
or
iz
on
ta
l r
id
ge
 w
id
th
) 
Width at 0 mm 
(µm) 
2547.8 
1714.7 
2701.9 
Low:1015.3  
Up: 4080.3 
2096.8 
1602.0 
2403.3 
Low: 496.5 
Up: 3697.1 
168.9 
239.7 
0.0 
Low: -45.4 
Up: 383.1 
1430.2 
1369.4 
833.9 
Low: 206.3 
Up: 2654.2 
1862.6 
1898.0 
1450.6 
Low: -33.4  
Up: 3758.6 
366.3 
620.0 
0.0 
Low: -187.8 
Up: 920.5 
554.7 
780.1 
301.9 
Low: -142.5 
Up: 1251.8 
231.3 
318.5 
0.0 
Low: -53.3 
Up: 515.9 
71.8 
190.0 
0.0 
Low: -98.0 
Up: 241.6 
Width at 1.5 mm 
(µm) 
1324.1 
773.1 
1233.7 
Low: 633.1 
Up: 2015.1 
1371.8 
683.2 
1485.7 
Low: 689.3 
Up: 2054.2 
248.2 
350.3 
70.0 
Low: -64.9 
Up: 561.3 
816.8 
665.5 
655.9 
Low: 222.1 
Up: 1411.6 
687.8 
569.8 
563.7 
Low: 118.6 
Up: 1256.9 
345.8 
433.2 
130.9 
Low: -41.4 
Up: 733.0 
635.9 
227.7 
644.7 
Low: 432.5 
Up: 839.4 
679.3 
596.7 
674.9 
Low: 146.0 
Up: 1212.6 
288.9 
434.9 
156.9 
Low: -99.8 
Up: 677.6 
Width at 3.5 mm 
(µm) 
1352.3 
751.2 
1187.6 
Low: 680.9 
Up: 2023.7 
1843.5 
850.3 
1542.7 
Low: 994.1 
Up: 2693.0 
660.5 
511.5 
425.7 
Low: 203.4 
Up: 1117.7 
804.4 
569.2 
739.8 
Low: 295.7 
Up: 1313.2 
1160.4 
489.2 
1230.7 
Low: 671.7 
Up: 1649.2 
435.2 
317.5 
305.0 
Low: 151.5 
Up: 718.9 
701.9 
229.6 
617.3 
Low: 496.7 
Up: 907.1 
810.8 
285.2 
841.9 
Low: 555.8 
Up: 1065.7 
348.2 
323.8 
274.6 
Low: 58.8 
Up: 637.5 
Width at 5.5 mm 
(µm) 
852.1 
500.9 
818.2 
Low: 404.4 
Up: 1299.8 
1433.8 
1042.6 
1255.3 
Low: 392.3 
Up: 2475.3 
524.0 
413.1 
377.8 
Low: 154.8 
Up: 893.3 
594.2 
595.1 
420.0 
Low: 62.3 
Up: 1126.0 
1208.6 
426.7 
1154.4 
Low: 782.3 
Up: 1634.9 
641.2 
382.3 
585.6 
Low: 299.6 
Up: 982.8 
647.4 
299.5 
671.1 
Low: 379.7 
Up: 915.0 
466.4 
196.4 
472.1 
Low: 290.9 
Up: 642.0 
324.4 
83.8 
309.2 
Low: 249.5 
Up: 399.2 
Width at 7.5 mm 
(µm) 
494.7 
330.0 
541.8 
Low: 199.8 
Up: 789.6 
897.1 
869.6 
528.6 
Low: 28.4 
Up: 1765.8 
471.0 
503.7 
363.7 
Low: 20.8 
Up: 921.2 
419.0 
397.6 
232.3 
Low: 63.6 
Up: 774.4 
817.8 
655.6 
718.7 
Low: 162.9 
Up: 1472.7 
374.7 
240.9 
377.7 
Low: 159.4 
Up: 590.1 
314.3 
243.9 
287.1 
Low: 96.3 
Up:532.3 
281.0 
342.3 
202.5 
Low: -25.0 
Up: 587.0 
322.9 
362.9 
181.9 
Low: -1.4 
Up: 647.3 				
	
Table 2 
Inter-group comparison  ANOVA, Tukey, Games-Howell  
 
 
 
Augmented soft 
tissue thickness 
0 mm  µm   
Augmented soft 
tissue thickness 
1.5 mm  µm  
Augmented soft 
tissue thickness 
3.5 mm  µm   
Augmented soft 
tissue thickness 
5.5 mm  µm  
Augmented soft 
tissue thickness 
7.5 mm  µm   
4 
w
ee
ks
 SCTG vs Control p = 0.019* p = 0.012* p = 0.191  p =.655  p = 0.997  
SCTG vs VCMX p = 0.877 p = 0.990  p = 0.443  p =.305  p = 0.459  
Control vs VCMX p = 0.058  p = 0.011*  p = 0.019* p = 0.069  p = 0.419  
8 
w
ee
ks
 SCTG vs Control  p = 0.198  p = 0.287  p = 0.328  p = 0.982  p = 0.982  
SCTG vs VCMX p = 0.889  p = 0.911  p = 0.377  p = 0.077  p = 0.276  
Control vs VCMX p = 0.222  p = 0.530  p = 0.030*  p = 0.108  p = 0.209  
24
 w
ee
ks
 SCTG vs Control p = 0.190  p = 0.332  p = 0.071  p = 0.025*  p = 0.999  
SCTG vs VCMX p = 0.459  p = 0.982  p = 0.754  p = 0.270  p = 0.979  
Control vs VCMX p = 0.823  p = 0.253  p = 0.015*  p = 0.437  p = 0.968  					
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